Your Source for Venture Capital and Private Equity Financings

VC-funded Company:

Hillstar Bio

Hillstar Bio is ushering in a new era in autoimmune disease treatment through precision immunology. The company selectively targets and depletes pathogenic immune cells while sparing healthy ones, offering the potential for durable relief and immune reset for patients with autoimmune conditions. Unlike traditional therapies that broadly suppress the immune system, Hillstar Bio's targeted approach addresses specific disease mechanisms by eliminating the underlying source and reducing the risks associated with chronic broad immunosuppression. =

Key Contact
Name
Robert Mabry, Ph.D.
Title
CEO
Funding Events

Date
Amount
Type
Investors
Valuation
03/25/25 $67,000,000 Series A DROIA Ventures
Frazier Life Sciences
Hummingbird Bioscience
LifeArc
Novo Holdings
undisclosed